Gossamer Bio, Inc. (GOSS)
Automate Your Wheel Strategy on GOSS
With Tiblio's Option Bot, you can configure your own wheel strategy including GOSS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GOSS
- Rev/Share 0.5493
- Book/Share -0.0276
- PB -46.8152
- Debt/Equity -32.3094
- CurrentRatio 5.7125
- ROIC -0.2399
- MktCap 293219580.0
- FreeCF/Share -0.4729
- PFCF -2.7336
- PE -5.7105
- Debt/Assets 0.7197
- DivYield 0
- ROE -1.2898
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenheimer Yasmeen Rahimi - Piper Sandler & Co. Paul Choi - Goldman Sachs Olivia Brayer - Cantor Patrick Trucchio - HC Wainwright Laura Chico - Wedbush Operator Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 …
Read More
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio.
Read More
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.
Read More
About Gossamer Bio, Inc. (GOSS)
- IPO Date 2019-02-08
- Website https://www.gossamerbio.com
- Industry Biotechnology
- CEO Mr. Faheem Hasnain
- Employees 144